Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Author(s): Vishal Bhatia, Ashwani K. Dhingra*, Bhawna Chopra and Kumar Guarve

DOI: 10.2174/1871527321666220301122807

DownloadDownload PDF Flyer Cite As
A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development

Page: [41 - 50] Pages: 10

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Major depression is a debilitating, sometimes fatal disorder, deteriorating the quality of life and well-being. Escitalopram showed highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs to manage major depressive disorder (MDD).

Objective: The objective of this study is to explore the therapeutic potential of escitalopram, a clinically approved drug to manage MDD and panic disorders.

Methods: It emphasizes comparative and clinical trial studies with several pharmacological targets reviewed from the data available on PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations.

Results: To highlight the clinical efficacy, safety, recent development, and stable formulation of escitalopram with an increased bioavailability profile. Evidence-based on the available clinical and pharmacoeconomic data, escitalopram represents an effective first-line treatment option for MDD patients.

Conclusion: The present review highlights the placebo-controlled clinical studies and the recent development that can be helpful for further research perspectives.

Keywords: Escitalopram, citalopram, MDD, SSRIs, SNRIs, clinical trials.

Graphical Abstract

[1]
Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17(5): 343-62.
[http://dx.doi.org/10.2165/00023210-200317050-00004] [PMID: 12665392]
[2]
Sánchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003; 167(4): 353-62.
[http://dx.doi.org/10.1007/s00213-002-1364-z] [PMID: 12719960]
[3]
Chen F, Larsen MB, Sánchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15(2): 193-8.
[http://dx.doi.org/10.1016/j.euroneuro.2004.08.008] [PMID: 15695064]
[4]
Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45(2): 167-73.
[http://dx.doi.org/10.1016/S0028-3908(03)00138-2] [PMID: 12842122]
[5]
El Mansari M, Sánchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005; 30(7): 1269-77.
[http://dx.doi.org/10.1038/sj.npp.1300686] [PMID: 15702136]
[6]
Kimura M. Escitalopram oxalate. J Jpn Soc Hosp Pharm 2012; 48: 371-5.
[7]
Kleemann A. Anti-depressants. In: Wiley VCH, Ed. Ullmann’s Encyclopedia of Industrial Chemistry. (7th ed.), New York: John Wiley & Sons 2014.
[8]
Murdoch D, Keam SJ. Escitalopram: A review of its use in the management of major depressive disorder. Drugs 2005; 65(16): 2379-404.
[http://dx.doi.org/10.2165/00003495-200565160-00013] [PMID: 16266205]
[9]
Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50(5): 345-50.
[http://dx.doi.org/10.1016/S0006-3223(01)01145-3] [PMID: 11543737]
[10]
Dhillon S, Scott LJ, Plosker GL. Escitalopram: A review of its use in the management of anxiety disorders. CNS Drugs 2006; 20(9): 763-90.
[http://dx.doi.org/10.2165/00023210-200620090-00010] [PMID: 16953656]
[11]
Chen F, Larsen MB, Neubauer HA, Sánchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005; 92(1): 21-8.
[http://dx.doi.org/10.1111/j.1471-4159.2004.02835.x] [PMID: 15606893]
[12]
Neubauer HA, Hansen CG, Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter: A cross-species study. Mol Pharmacol 2006; 69(4): 1242-50.
[http://dx.doi.org/10.1124/mol.105.018507] [PMID: 16434615]
[13]
Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174(2): 163-76.
[http://dx.doi.org/10.1007/s00213-004-1865-z] [PMID: 15160261]
[14]
Klein N, Sacher J, Geiss-Granadia T, et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007; 191(2): 333-9.
[http://dx.doi.org/10.1007/s00213-006-0666-y] [PMID: 17235610]
[15]
Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30(7): 1206-27.
[http://dx.doi.org/10.1016/S0149-2918(08)80047-1] [PMID: 18691982]
[16]
Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17(3): 95-102.
[http://dx.doi.org/10.1097/00004850-200205000-00001] [PMID: 11981349]
[17]
Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63(4): 331-6.
[http://dx.doi.org/10.4088/JCP.v63n0410] [PMID: 12000207]
[18]
Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18(4): 211-7.
[http://dx.doi.org/10.1097/01.yic.0000074988.54339.7c] [PMID: 12817155]
[19]
Lalit V, Appaya PM, Hegde RP, et al. Escitalopram versus citalopram and sertraline: A double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian J Psychiatry 2004; 46(4): 333-41.
[PMID: 21206792]
[20]
Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3): 131-7.
[http://dx.doi.org/10.1097/00004850-200505000-00002] [PMID: 15812262]
[21]
Ou JJ, Xun GL, Wu RR, et al. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology (Berl) 2011; 213(2-3): 639-46.
[http://dx.doi.org/10.1007/s00213-010-1822-y] [PMID: 20340011]
[22]
Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007; 29(11): 2319-32.
[http://dx.doi.org/10.1016/j.clinthera.2007.11.014] [PMID: 18158074]
[23]
Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared to citalopram: A meta-analysis. Int J Neuropsychopharmacol 2011; 14(2): 261-8.
[http://dx.doi.org/10.1017/S146114571000115X] [PMID: 20875220]
[24]
Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J 2010; 51(1): 61-73.
[http://dx.doi.org/10.3325/cmj.2010.51.61] [PMID: 20162747]
[25]
Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22(7): 1331-41.
[http://dx.doi.org/10.1185/030079906X115513] [PMID: 16834832]
[26]
Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006; 21(3): 159-69.
[http://dx.doi.org/10.1097/01.yic.0000194377.88330.1d] [PMID: 16528138]
[27]
Hirayasu Y. A dose-response and non-inferiority study evaluating the efficacy and safety of escitalopram in patients with major depressive disorder: A placebo- and paroxetine-controlled, double-blind, comparative study. Jpn J Clin Psychopharmacol 2011; 14: 883-99.
[28]
Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety 2008; 25(1): 46-54.
[http://dx.doi.org/10.1002/da.20222] [PMID: 17149753]
[29]
Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: A randomized clinical trial. Curr Med Res Opin 2007; 23(2): 245-50.
[http://dx.doi.org/10.1185/030079906X167273] [PMID: 17288677]
[30]
Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007; 27(7): 481-92.
[http://dx.doi.org/10.2165/00044011-200727070-00005] [PMID: 17563128]
[31]
Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23(7): 1605-14.
[http://dx.doi.org/10.1185/030079907X210732] [PMID: 17559755]
[32]
Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65(9): 1190-6.
[http://dx.doi.org/10.4088/JCP.v65n0906] [PMID: 15367045]
[33]
Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50(1): 57-64.
[http://dx.doi.org/10.1159/000078225] [PMID: 15179022]
[34]
Hirayasu Y. A long-term administration study of escitalopram in patients with major depressive disorders. Jpn J Clin Psychopharmacol 2011; 14: 901-12.
[35]
Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15(7): 581-93.
[http://dx.doi.org/10.1097/01.JGP.0000240823.94522.4c] [PMID: 17586783]
[36]
Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67(11): 1767-75.
[http://dx.doi.org/10.4088/JCP.v67n1115] [PMID: 17196058]
[37]
Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin 2009; 25(1): 161-75.
[http://dx.doi.org/10.1185/03007990802622726] [PMID: 19210149]
[38]
Assistance Publique - Hopitaux de Paris. Serotonin transporter inhibitor escitalopram in pulmonary hypertension. Available from: https://clinicaltrials.gov/ct2/show/NCT00190333 (Accessed: August 5, 2021).
[39]
Lundbeck H. Escitalopram in patients with social anxiety disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00902226 (Accessed: August 5, 2021).
[40]
Lundbeck H. Escitalopram in patients with generalized anxiety disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00902564 (Accessed: August 5, 2021).
[41]
Charite University, Berlin, Germany.. Investigation of a combination treatment of escitalopram and rTMS Available from: https://clinicaltrials.gov/ct2/show/NCT00232700 (Accessed: August 5, 2021).
[42]
Seoul National University Hospital. Comparison of effects between conventional dose and high dose escitalopram on clinical improvement in patients with obsessive-compulsive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00723060 (Accessed: August 5, 2021).
[43]
BC Women’s Hospital & Health Centre. Escitalopram in the treatment of postpartum depression. Available from: https://clinicaltrials.gov/ct2/show/NCT01527474 (Accessed: August 5, 2021).
[44]
University of Rochester. Escitalopram treatment of patients with agitated dementia. Available from: https://clinicaltrials.gov/ct2/show/NCT00260624 (Accessed: August 5, 2021).
[45]
Forest Laboratories. Study of Escitalopram in adult patients with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00108979 (Accessed: August 5, 2021).
[46]
Forest Laboratories. Comparison of escitalopram combination in adult patients with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00109044 (Accessed: August 5, 2021).
[47]
Hopital Jean Minjoz. MOTIV Study- effect of antidepressive treatment by escitalopram in patients undergoing coronary artery bypass grafting Available from: https://clinicaltrials.gov/ct2/show/NCT00243477 (Accessed: August 5, 2021).
[48]
Pharmacology Research Institute. Escitalopram combination comparison study for adult patients with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00239954 (Accessed: August 5, 2021).
[49]
Beitou Armed Forces Hospital. The effects of escitalopram on cytokines (BAFH) Available from: https://clinicaltrials.gov/ct2/show/NCT01587326 (Accessed: August 5, 2021).
[50]
Baylor College of Medicine. Modafinil - escitalopram study for cocaine dependence Available from: https://clinicaltrials.gov/ct2/show/NCT01601730 (Accessed: August 5, 2021).
[51]
Seoul National University Hospital. Neuroprotective/neurotrophic effect of lexapro® in patients with posttraumatic stress disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT01008098 (Accessed: August 5, 2021).
[52]
Karolinska Institutet. A PET study to determine alterations in serotonin levels in human brain after a single dose of escitalopram. Available from: https://clinicaltrials.gov/ct2/show/NCT01638689 (Accessed: August 5, 2021).
[53]
Lehigh Center for Clinical Research. Eszopiclone co-administered with escitalopram for insomnia in elderly adults with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT00813735 (Accessed: August 5, 2021).
[54]
Lundbeck H. Bioequivalence study comparing two formulations of escitalopram. Available from: https://clinicaltrials.gov/ct2/show/NCT01395433 (Accessed: August 5, 2021).
[55]
Samsung Medical Center. Comparison of tianeptine versus escitalopram patients major depressive disorder (CAMPION). Available from: https://clinicaltrials.gov/ct2/show/NCT01309776 (Accessed: August 5, 2021).
[56]
National Institute of Mental Health (NIMH). Lexapro and pramipexole and to treat major depression. Available from: https://clinicaltrials.gov/ct2/show/NCT00086307 (Accessed: August 5, 2021).
[57]
Ludwig-Maximilians - University of Munich. Quetiapine prolong, escitalopram and hypothalamic-pituitary-adrenocortical (HPA) axis activity in depressed patients. Available from: https://clinicaltrials.gov/ct2/show/NCT00953108 (Accessed: August 5, 2021).
[58]
Fred Hutchinson Cancer Research Center. MsFLASH-01: Escitalopram for menopausal symptoms in midlife women. Available from: https://clinicaltrials.gov/ct2/show/NCT00894543 (Accessed: August 5, 2021).
[59]
Duke University. Escitalopram (Lexapro®) In patients with major depression with atypical features Available from: https://clinicaltrials.gov/ct2/show/NCT00610506 (Accessed: August 5, 2021).
[60]
Baker heart and diabetes institute. Cardiovascular effects of agomelatine and escitalopram in patients with major depressive disorder (MDD). Available from: https://clinicaltrials.gov/ct2/show/NCT01483053 (Accessed: August 7, 2021).
[61]
Xian-janssen pharmaceutical Ltd. A safety and efficacy study of escitalopram on acute treatment of severe depression. Available from: https://clinicaltrials.gov/ct2/show/NCT01814085 (Accessed: August 7, 2021).
[62]
Forest Laboratories. Safety study of Escitalopram in children 7 to 11 years of age with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT01198795 (Accessed: August 7, 2021).
[63]
Seoul National University Hospital. A clinical trial to investigate the pharmacokinetics and the effect on ECG of Escitalopram in elderly volunteers. Available from: https://clinicaltrials.gov/ct2/show/NCT02122939 (Accessed: August 7, 2021).
[64]
Massachusetts general hospital. Influence of escitalopram on fear conditioning Available from: https://clinicaltrials.gov/ct2/show/NCT01398514 (Accessed: August 7, 2021).
[65]
Massachusetts General Hospital. Escitalopram (Lexapro) for the treatment of postpartum depression (LexaproPPD) Available from: https://clinicaltrials.gov/ct2/show/NCT00833469 (Accessed: August 7, 2021).
[66]
Duke University. Treatment effects of escitalopram (lexapro®) on generalized anxiety disorder in patients with HIV and AIDS Available from: https://clinicaltrials.gov/ct2/show/NCT00887679 (Accessed: August 7, 2021).
[67]
Abarbanel Mental Health Center. The effect of patient and investigator expectation on the efficacy of Escitalopram in the treatment depression. Available from: https://clinicaltrials.gov/ct2/show/NCT02480400 (Accessed: August 7, 2021).
[68]
Samsung Medical Center. Development of Escitalopram genomic device by using candidate gene approach and genome-wide scanning. Available from: https://clinicaltrials.gov/ct2/show/NCT00935246 (Accessed: August 7, 2021).
[69]
Roussy G, Campus C. Gustave Roussy, Cancer Campus, Grand Paris. Randomized, double blind, efficacy study of escitalopram in ENT cancer patients suffering from emotional distress (TADDOR) Available from: https://clinicaltrials.gov/ct2/show/NCT02246244 (Accessed: August 7, 2021).
[70]
Xian-Janssen Pharmaceutical Ltd. A Study to evaluate the impact of Escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom. Available from: https://clinicaltrials.gov/ct2/show/NCT01870843 (Accessed: August 7, 2021).
[71]
Indiana University School of Medicine. Study of brain response to emotional pictures using a magnetic resonance imaging (fMRI) while on Escitalopram Available from: https://clinicaltrials.gov/ct2/show/NCT00707863 (Accessed: August 5, 2021).
[72]
Massachusetts General Hospital. Brain Energy Metabolism in Individuals with Major Depressive Disorder Receiving Escitalopram. Brain energy metabolism in individuals with major depressive disorder receiving Escitalopram Available from: https://clinicaltrials.gov/ct2/show/NCT00183677 (Accessed: August 7, 2021).
[73]
Maastricht University Medical Center. Escitalopram trial for irritable bowel syndrome (IBS) patients with panic disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT01551225 (Accessed: August 7, 2021).
[74]
H. Lundbeck A/S. Efficacy of vortioxetine versus escitalopram on cognitive function in patients with inadequate response to current antidepressant treatment of major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT02272517 (Accessed: August 7, 2021).
[75]
Erzurum regional training & research hospital. Escitalopram in the treatment of adolescents with major depressive disorder or anxiety disorders Available from: https://clinicaltrials.gov/ct2/show/NCT03122158 (Accessed: August 7, 2021).
[76]
GlaxoSmithKline. Bioequivalence study of Escitalopram tablets 10 mg. Available from: https://clinicaltrials.gov/ct2/show/NCT01745601 (Accessed: August 7, 2021).
[77]
Xian-Janssen Pharmaceutical Ltd. An efficacy and safety study of escitalopram long-term treatment in major depressive disorder with associated anxiety symptoms (Lexapro) Available from: https://clinicaltrials.gov/ct2/show/NCT01814098 (Accessed: August 7, 2021).
[78]
New York State Psychiatric Institute. Cognitive-behavioral therapy and escitalopram for generalized anxiety disorder (GAD) Available from: https://clinicaltrials.gov/ct2/show/NCT00219349 (Accessed: August 7, 2021).
[79]
Seoul National University Hospital. Lexapro®'s efficacy after dose escalation in remission study (LEADERS) Available from: https://clinicaltrials.gov/ct2/show/NCT01594866 (Accessed: August 7, 2021).
[80]
Max-Planck-Institute of Psychiatry. Pharmacokinetic and pharmacodynamic effects of escitalopram depending on genetic polymorphisms of the ABCB1-gene. Available from: https://clinicaltrials.gov/ct2/show/NCT00550485 (Accessed: August 10, 2021).
[81]
University of South Carolina. Escitalopram (Lexapro) for depression MS or ALS. Available from: https://clinicaltrials.gov/ct2/show/NCT00965497 (Accessed: August 10, 2021).
[82]
VA Nebraska Western Iowa Health Care System. Effects of Escitalopram on autonomic reactivity in post traumatic stress disorder Available from: https://clinicaltrials.gov/ct2/show/NCT01271244 (Accessed: August 10, 2021).
[83]
Peking University Sixth Hospital. Effects of Escitalopram on the sleep EEG power in patients with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT04013464 (Accessed: August 10, 2021).
[84]
GlaxoSmithKline. Study to evaluate the efficacy, safety and tolerability of bupropion hydrochloride extended-release tablet, and escitalopram oxalate capsule in subjects with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT02191397 (Accessed: August 10, 2021).
[85]
Shaheed Zulfiqar Ali Bhutto Medical University. Comparative efficacy of duloxetine vs escitalopram in patients with fibromyalgia (CORTEX) Available from: https://clinicaltrials.gov/ct2/show/NCT03487211 (Accessed: August 10, 2021).
[86]
Augusta University. SAT vs. Escitalopram for rectal hypersensitivity. Available from: https://clinicaltrials.gov/ct2/show/NCT00584571 (Accessed: August 10, 2021).
[87]
University of Cincinnati. Neurofunctional predictors of escitalopram treatment response in adolescents with anxiety (FiESTAA). Available from: https://clinicaltrials.gov/ct2/show/NCT02818751 (Accessed: August 10, 2021).
[88]
Emory University. Bupropion versus Escitalopram on reward circuitry and motivational deficits. Available from: https://clinicaltrials.gov/ct2/show/NCT04352101 (Accessed: August 10, 2021).
[89]
Norwegian University of Science and Technology. Bariatric surgery and pharmacokinetics of Escitalopram. Available from: https://clinicaltrials.gov/ct2/show/NCT03460379 (Accessed: August 10, 2021).
[90]
Weill Medical College of Cornell University. Impact of Escitalopram on sperm DNA fragmentation. Available from: https://clinicaltrials.gov/ct2/show/NCT03527043 (Accessed: August 10, 2021).
[91]
Georgetown University. Treatments for anxiety: Meditation and Escitalopram (TAME) Available from: https://clinicaltrials.gov/ct2/show/NCT03522844 (Accessed: August 10, 2021).
[92]
University of Cincinnati. Pharmacogenetically-guided escitalopram treatment for pediatric anxiety: Aiming to improve safety and efficacy (PrEcISE) (PrEcISE) Available from: https://clinicaltrials.gov/ct2/show/NCT04623099 (Accessed: August 10, 2021).
[93]
Allergan. A Study of escitalopram in the treatment of children and adolescents with generalized anxiety disorder Available from: https://clinicaltrials.gov/ct2/show/NCT03924323 (Accessed: August 10, 2021).
[94]
American Society of Health-System Pharmacists 2017. Drug Information. Bethesda, MD 2017; p. 2462.
[95]
NIH DailyMed. Current medication information for Lexapro (Escitalopram Oxalate) tablet, film coated; lexapro (Escitalopram Oxalate) solution Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13bb8267-1cab-43e5-acae55a4d957630a (Accessed: March 27, 2018).
[96]
Montejo AL, Prieto N, de Alarcón R, et al. Management strategies for antidepressant-related sexual dysfunction: A clinical approach. J Clin Med 2019; 8: 1640.
[http://dx.doi.org/10.3390/jcm8101640]
[97]
Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: A literature review. Sex Med Rev 2018; 6(1): 29-34.
[http://dx.doi.org/10.1016/j.sxmr.2017.07.002] [PMID: 28778697]
[98]
Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31(3): 257-62.
[http://dx.doi.org/10.1080/00926230590513474] [PMID: 16020143]
[99]
Gdziepolek.pl. Mozarin, zamienniki i podobne produkty. Available from: https://www.gdziepolek.pl/produkty/50443/mozarin-tabletki-powlekane/zamienniki (Accessed: October 17, 2020).
[100]
international: Escitalopram. Available from: https://www.drugs.com/escitalopram.html (Accessed: April 25, 2015).
[101]
Kirino E. Escitalopram for the management of major depressive disorder: A review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 2012; 6: 853-61.
[http://dx.doi.org/10.2147/PPA.S22495] [PMID: 23271894]
[102]
Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007; 61(4): 702-10.
[http://dx.doi.org/10.1111/j.1742-1241.2007.01335.x] [PMID: 17394446]
[103]
Mushtaque M, Muhammad IN, Fareed HSM, Ali A, Masood R. Development and pharmaceutical evaluation of oral fast dissolving thin film of escitalopram: A patient friendly dosage form. Pak J Pharm Sci 2020; 33(1): 183-9.
[PMID: 32122847]
[104]
Wang W, Song T, Wan X, Liu C, Zhao H, Fang L. Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. Int J Pharm 2017; 529(1-2): 391-400.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.089] [PMID: 28673858]
[105]
Alkahtani ME, Aodah AH, Abu AOA, Basit AW, Orlu M, Tawfik EA. Fabrication and characterization of fast-dissolving films containing escitalopram/quetiapine for the treatment of major depressive disorder. Pharmaceutics 2021; 13(6): 891.
[http://dx.doi.org/10.3390/pharmaceutics13060891] [PMID: 34208460]
[106]
Navarro V. Improving medication compliance in patients with depression: Use of orodispersible tablets. Adv Ther 2010; 27(11): 785-95.
[http://dx.doi.org/10.1007/s12325-010-0073-y] [PMID: 20878372]
[107]
Shahzad Y, Maqbool M, Hussain T, et al. Natural and semisynthetic polymers blended orodispersible films of citalopram. Nat Prod Res 2020; 34(1): 16-25.
[http://dx.doi.org/10.1080/14786419.2018.1552698] [PMID: 30663358]
[108]
Kucka M. Tomić M, Bjelobaba I, Stojilkovic SS, Budimirovic DB. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Sci Rep 2015; 5(1): 8902.
[http://dx.doi.org/10.1038/srep08902] [PMID: 25754735]